Skip to main content
Livermore
Livermore
ZHEN

Two Sigma Advisers, LP

SEC CIK
0001478735
Latest filing
Aug 14, 2026

ALNY holding history

Alnylam Pharmaceuticals, Inc. in every 13F filed by Two Sigma Advisers, LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ALNY overviewAll 13F holders of ALNYFull Q2 2026 holdings

Shares (Q1 2026)
0
Sold out in Q1 2026
Value
$0
% of portfolio
0.0%
Quarters held
17
Since Q1 2021
Holdings of ALNY by Two Sigma Advisers, LP, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q1 20260$00.0%−1,132,560−100.0%Sold outHolders
Q4 20251,132,560$450.4M0.9%+240,060+26.9%AddedHolders
Q3 2025892,500$407.0M0.8%+626,400+235.4%AddedHolders
Q2 2025266,100$86.8M0.2%−9,700−3.5%ReducedHolders
Q1 2025275,800$74.5M0.2%+197,000+250.0%AddedHolders
Q4 202478,800$18.5M<0.1%−24,300−23.6%ReducedHolders
Q3 2024103,100$28.4M0.1%−155,600−60.1%ReducedHolders
Q2 2024258,700$62.9M0.1%+69,100+36.4%AddedHolders
Q1 2024189,600$28.3M0.1%+189,600NewHolders
Q4 20230$00.0%−35,900−100.0%Sold outHolders
Q3 202335,900$6.36M<0.1%−157,700−81.5%ReducedHolders
Q2 2023193,600$36.8M0.1%+38,500+24.8%AddedHolders
Q1 2023155,100$31.1M0.1%+35,100+29.3%AddedHolders
Q4 2022120,000$28.5M0.1%+56,200+88.1%AddedHolders
Q3 202263,800$12.8M<0.1%+51,400+414.5%AddedHolders
Q2 202212,400$1.81M<0.1%−34,300−73.4%ReducedHolders
Q1 202246,700$7.63M<0.1%+42,900+1,128.9%AddedHolders
Q4 20213,800$644.0K<0.1%+3,800NewHolders
Q2 20210$00.0%−31,900−100.0%Sold outHolders
Q1 202131,900$4.50M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.